INTRODUCTION
This voluntary whole body donation to the United States Transuranium and Uranium Registries (USTUR) provides a detailed and complete data record of one of the earliest cases of accidental acute inhalation of 'soluble' plutonium treated promptly with intravenously (i.v.) administered Ca-EDTA (in 1956 ). The donation is also unique because it traces the early evolution of chelation treatments, including several unsuccessful trials of orally-administered agents and, most notably, the introduction of i.v. Ca-DTPA therapy (2½ years after the intake, in late 1958). Over the succeeding four decades, intravenous injections of Ca-DTPA, or the potentially less toxic Zn-DTPA, have been used quite often as 'experimental' drugs to 'de-corporate' high intakes of plutonium. (1, 2) However, to date, no mechanistic model has been developed to predict quantitatively the effectiveness of a given course of therapy. (3) The objective of this study is to quantify (model) the effects of both the Ca-EDTA and Ca-DTPA treatments on plutonium elimination from the various tissue compartments represented in the ICRP Publication 67 Pu biokinetic model (IC67). (4) Concerns over a terrorist radionuclide dispersal threat have recently prompted regulatory approval of diethylenetriaminepentaacetic acid (DTPA) for medically supervised use to treat people internally contaminated with transuranics (plutonium, americium, or curium) (http://www.fda.gov/cder/drug/infopage/dtpa/).
THE DONOR'S INTAKE AND TREATMENT
This gentleman was an operator of the Pu reduction-oxidation (REDOX) process at the Hanford Engineering Works (HEW). He was accidentally contaminated externally and internally following a substantial release of plutonium in the form of an acidic Pu(NO 3 ) 4 aerosol mist. The precise time of the release was indicated by the instantaneous response of a stationary "poppy" survey meter in an adjacent change room. The donor provided 3 urine samples within 12 h of the intake, when a 'week-on, week-off' course of 1-g i.v. Ca-EDTA injections was started. The donor was restricted from all further work in radiation zones.
Intermittent treatments with i.v. Ca-EDTA were continued through about 6 months after the intake. The daily urinary excretion of Pu was then monitored several times per week through about 3-y after the intake, when intermittent treatment with 1-g i.v. Ca-DTPA was started. This treatment was continued for about 2 y. Faecal excretion of Pu was monitored, from day 1 through 35 y. In 1962, i.e., 6 y after the intake, the employer estimated that the donor's initial systemic 'burden' was 0.42 µCi (15.5 kBq), based on the contemporary graphical methods of analysing Pu excretion in urine. (5, 6) This was about 10× the 'maximum permissible body burden' (MPBB). (7) BIOASSAY DATA Figure 1 shows that daily i.v. injections of Ca-EDTA increased the excretion of Pu in urine about 8-fold over the 'baseline' (untreated) rate. Within a day of finishing each series of Ca-EDTA injections, the urinary excretion rate dropped back to the baseline value. The approximate 8-fold enhancement in Pu excretion was maintained throughout the 6-month period of treatment. These Ca-EDTA injections had no effect on the faecal excretion of Pu (Figure 2 ). Remarkably, Table 1 shows that about 1% of the total 239+240 Pu body burden at death remained in the lungs (38 y after the intake). This residue is about 2 orders of magnitude higher than the amount expected in blood, and is inconsistent with that expected (zero) for 'soluble' Pu (ICRP default Type M). Also, the 239+240 Pu concentration in the thoracic lymph nodes (LNTH) was about the same as that in the lungs. If the long-term retention had resulted from an 'insoluble' (particle) component in the inhaled aerosol, the LNTH concentration would have been two orders of magnitude higher than that in the lungs. Therefore, it can be inferred that this observed long-term retained Pu is the residue of material initially 'bound' to lung tissues.
ANALYSIS OF INTAKE
The IMBA Expert™ USDOE-Edition code (9) was used to define the absorption and lung retention behaviour of the inhaled Pu(NO 3 ) 4 aerosol, by fitting simultaneously the baseline (untreated) urinary and faecal Pu excretion data and the lung and lymph node contents measured at the time of death (14,054 d post intake), as described for Case 0262. (10) Again, the fitting procedure was constrained to predict exactly the measured lung and LNTH contents, while simultaneously minimizing the value of (Σχ 2 urine + Σχ 2 faeces ). The resulting 'maximum likelihood' values of the critical intake and absorption parameters for the ICRP Publication 66 model (IC66) (11) were:
• Intake ≈ 58 kBq.
• AMAD ≈ 2 µm.
• Gut absorption fraction, f 1 ≈ 0.0005.
These estimated parameter values were obtained by using the default transfer rates for systemic Pu recommended by ICRP for Reference Man.
(4) Thus, no account was taken of any effect of the chelation therapies in accelerating the elimination of Pu from the body; the analysis was carried out using only the observed baseline (untreated) excretion rates. It was determined that a 'reasonable' statistical fit to the observed baseline excretion rates yielded a projected value of the 'untreated' body burden at the time of death (38 y post intake) of 3.9 kBq. This projected value is about 1.7× the measured total body burden (2.3 kBq), indicating a substantial overall effect of the chelation treatments in this case.
BIOKINETIC MODEL SYSTEM
The combined respiratory tract and systemic Pu biokinetic model system solved by the IMBA Expert™ software is shown in Figure 3 . In order to examine the effects of modifying the values of key rate constants in the IC67 (4) systemic Pu model on the urinary and faecal excretion of Pu (in specified time intervals), together with their effects on projected Pu tissue contents (at the time of death), the 'rate matrix' algorithm was used to solve the complete biokinetic system. This was done in time steps corresponding to all discrete chelation treatments (i.v. Ca-EDTA or i.v. Ca-DTPA) and the corresponding excreta collection periods (treated or untreated). In order to represent the direct effects of these chelating agents, the ICRP-recommended transfer rates for each pathway highlighted in Figure 4 were multiplied by an agent-specific 'trial' factor (K pathway,agent ). These trial values of K pathway,agent were then varied iteratively (in pairs) to minimise the value of (Σχ 2 urine + Σχ 2 faeces ), while preserving a reasonably accurate prediction of the 239+240 Pu contents of the measured tissue contents. As an example, Figure 5 shows the χ 2 'hyper-surface' obtained by co-varying the K-factors for the 'blood → urinary path' and 'blood → bladder content' pathways during periods of i.v. Ca-EDTA therapy. The transfer rate modifying factors derived for both i.v. Ca-EDTA ( Figure 6 ) and Ca-DTPA ( Figure  7 ) accurately predict the observed enhancements in daily excretion of Pu in urine. They also predict the upward shift in the baseline urinary Pu excretion rate compared to that predicted for 'no treatment' (by the IC67 Pu biokinetic parameter values). The observed enhancement of faecal Pu excretion influenced by i.v. Ca-DTPA therapy (Figure 8 ) is also predicted. However, the modeled enhancement factor for the 'Liver-1 → SI' pathway (Figure 4) , fitted in combination with the other rate enhancement factors, does not yet represent accurately the long-term 'baseline' (systemic) faecal Pu excretion. The inferred ability of delayed i.v. Ca-DTPA to decorporate a significant amount of Pu from bone surfaces and bone marrow confirms the much earlier quantitative observations of these processes in experimental animals (weanling rats). (12) In this human case, the ratios of 239+240 Pu concentrations measured in trabeculated bones : that measured in cortical bone was significantly lower than the range found in other (non-chelated) USTUR cases.
DERIVED DECORPORATION EFFECTIVENESS

CONCLUSION AND COMMENTS
The study outlined here is a 'work in progress. ' The analytical methods applied and the resulting detailed model of the effects of i.v. Ca-EDTA and Ca-DTPA treatment in terms of specific 'transfer-rateenhancement' factors will be described elsewhere. (13) These case data are currently being re-analysed for final publication by substituting the recently reported 'modified' Pu biokinetic model of Leggett et al. (14) as the 'baseline,' in place of the IC67 model used here. The newer model treats the early kinetics of Pu transfer between two blood compartments and tissue fluid in a manner that is consistent with the results of European biokinetic studies with human volunteers. (15, 16) Planned further study of the Case 0269 data includes extension of the modeling process to evaluate the effects of the Ca-EDTA and Ca-DTPA therapies in decorporating in-grown 241 Am from body tissues. USTUR has determined the 241 Pu content of the inhaled Pu material by measuring the amount of 241 Am in-growth in the original urine planchets (5 decades after the original chemical separation).
However, it is already clear from this initial study that both the i.v. Ca-EDTA and i.v. Ca-DTPA therapies administered in this case had substantial
